Risk of venous thromboembolism, use of enoxaparin and clinical outcomes in obese patients undergoing laparoscopic adjustable gastric band surgery

A retrospective study

Zahid Hussain, PhD, Gregory M. Peterson, PhD, Corinne Mirkazemi, PhD, Colin Curtain, PhD, Syed Tabish R. Zaidi, PhD

1. Introduction

Bariatric surgery is considered the most effective treatment in the management of morbid obesity and prevention of obesity-related complications.[1] The number of obese patients undergoing bariatric surgery has increased more than 10-fold in the past 2 decades.[2] One of the main reasons for this increase has been the development of laparoscopic techniques, which offer an excellent safety profile.[1] However, venous thromboembolism (VTE)
remains a significant cause of morbidity and mortality during the post-operative period. The incidence of VTE ranges from 0.2% to 3.5% in bariatric patients undergoing laparoscopic surgery.

Mechanical prophylaxis methods, such as thromboembolic deterrent stockings and sequential compression devices, and chemoprophylaxis, such as unfractionated heparin (UFH) or low molecular weight heparin (LMWH), are often used to prevent VTE in patients undergoing bariatric surgery. The routine use of mechanical prophylaxis is recommended by various guidelines, such as those of the American Society for Metabolic and Bariatric Surgery (ASMB), the American College of Chest Physicians (CHEST) and the National Institute for Health and Care Excellence (NICE). However, studies have reported inconsistent findings regarding the potential need, choice of drug, dosing regimen, and duration for VTE chemoprophylaxis. Generally, there is consensus that enoxaparin is more effective in VTE prevention compared to UFH, without increasing the bleeding risk in bariatric surgical patients. Yet, controversy regarding the use and dose of enoxaparin exists in the literature; recommendations have ranged from its use not being essential (mechanical prophylaxis alone is enough) to the use of high-dose enoxaparin (60 mg twice daily). Similarly, some studies have reported an extended duration of chemoprophylaxis for 10 days or 2 weeks post-discharge resulted in less VTE complications compared to in-hospital use only.

The ASMB position statement published in 2013 recommended there was no level 1 evidence regarding the type, dose and duration of chemoprophylaxis to be used in bariatric surgical patients. The CHEST guidelines published in 2012 recommended the use of LMWH or UFH in bariatric surgical patients who have moderate (grade 2B) or high (grade 1B) VTE risk; however, no information regarding the dose and duration of chemoprophylaxis was provided. The NICE guidelines published in 2018 suggested the use of chemoprophylaxis (LMWH or fondaparinux sodium) in all patients with low bleeding risk, and for it to be continued while the patient had significantly reduced mobility. Importantly, these guidelines did not distinguish between types of bariatric procedure (gastric bypass, sleeve gastrectomy, gastric banding) and surgical techniques (open vs laparoscopic) in regard to VTE prophylaxis.

In light of this variation and uncertainty, we retrospectively examined current local practice for chemoprophylaxis in patients undergoing primary and revisional bariatric surgery (laparoscopic adjustable gastric banding; LAGB). We estimated the risk of VTE in each patient using a post-discharge VTE risk assessment tool published by the Cleveland Clinic. We determined the use (dose and duration) of chemoprophylaxis and the incidence of adverse outcomes (VTE and bleeding events). Finally, we identified the factors associated with the use of chemoprophylaxis.

2. Methods

Ethical approval for this study was obtained from the Tasmanian Health and Human Research Ethics Committee (H0015795). The need for consent from patients was waived by the committee due to the retrospective nature of the study and the collection of non-identifiable patient information.

A retrospective study was conducted of adult (age ≥ 18 years) obese patients (body mass index (BMI) ≥ 30 kg/m²) who underwent primary and revisional bariatric surgery at the Royal Hobart Hospital and the Hobart Private Hospital, from January 1, 2013, to December 31, 2017. The sole primary bariatric procedure at our study sites was LAGB. Revisional procedures were done for adjustment, replacement, or removal of bands, as well as adjustment, replacement, or removal of ports. Patients were excluded from the study if they were on regular anticoagulant or vitamin K therapy, underwent a concurrent surgical procedure (e.g., hysterectomy), or had an established congenital or acquired bleeding disorder, varicose veins, renal impairment with an estimated glomerular filtration rate < 60 mL/min/1.73m², prior heparin-induced thrombocytopenia, haemorrhagic stroke within the previous 3 months, other surgery within the previous 3 months, or if relevant information was missing. Patients had been advised to stop taking any non-steroidal anti-inflammatory drugs and aspirin 5 days preoperatively.

A list of patients who had undergone primary and revisional LAGB during the study period was obtained from hospital coding databases. Patients’ medical records were reviewed to confirm eligibility and to collect demographic and clinical information, including age, gender, body mass index, length of hospital stay, duration of surgical procedure, American Society of Anaesthesiologists score; return to operating room, incidents of dyspnoea at rest, smoking status, presence of diabetes mellitus, hypertension, congestive heart failure, paraplegia, or obstructive sleep apnoea, history of VTE, oral contraceptive, or hormone replacement therapy (HRT) use, details of mechanical prophylaxis, use of prophylactic anticoagulant (including dose and duration), and the occurrence of VTE (deep vein thrombosis and/or pulmonary embolism; deep vein thrombosis, and/or pulmonary embolism), or major bleeding complications within 90 days following the procedure. Colour Doppler ultrasound and CT pulmonary angiography techniques were used for diagnosis of VTE at our study sites. To define major bleeding, we used the criteria of the International Society on Thrombosis and Haemostasis: fatal bleeding; bleeding in vital organs (intracranial, intraspinal, retroperitoneal, intra-articular, pericardial, intraocular); bleeding at a surgical site requiring reoperation; and bleeding associated with a reduction in haemoglobin of at least 2 g/dL or requiring transfusion of at least 2 units of packed red cells/whole blood.

Categorical variables were expressed as count (percentage) and continuous variables as median (range). Fisher exact test and Pearson X² test were used for categorical variables to compare primary and revisional procedures. The Kruskal–Wallis test was used for continuous variables to compare demographic and clinical variables and prophylactic anticoagulant usage for primary and revisional procedures. Univariate logistic regressions were used to identify variables associated with enoxaparin use. Subsequently, variables with a P-value < .15 in the univariate analyses, procedure type, and VTE risk were considered in a multivariate regression analysis.

We also compared outcomes for our primary procedure cohort with the American College of Surgeons-National Surgical Quality Improvement Programme (ACS-NSQIP) and the French National Health Care System (SNIRHM). Only the primary LAGB procedure cohort was compared because the published data do not include revisional procedures. The one proportion sample test was used to compare our incidence of VTE and major bleeding with these data.

3. Results

Out of 262 screened patients, 212 met the inclusion criteria (Fig. 1). One hundred twelve underwent primary LAGB and 100
had revisional (24 band and 76 port) procedures. Socio-demographic and clinical characteristics of the patients are presented in Table 1. Patients in both cohorts were predominantly female. The primary procedure cohort had a significantly higher mean weight and BMI. Primary and revisional band procedure patients had longer hospital lengths of stay (median of 1 day vs 0 days, \( P < .001 \)) compared to the port procedure patients. Almost all patients in the primary (95%), revisional band (100%) and revisional port procedures (99%) categories had mild risk of VTE.

Mechanical prophylaxis was used during hospital stay in 100% of patients undergoing primary procedures compared to 96% and 84% for revisional band and port procedures, respectively. All patients in the primary procedure cohort were given the combination of thromboembolic deterrent, sequential compression devices and enoxaparin, compared to 75% in the revisional band procedures and just 18% of patients in the revisional port procedures cohorts (\( P < .001 \)). Overall, 69% of patients received chemoprophylaxis. The use of prophylactic enoxaparin was significantly higher in the primary and revisional band procedure cohorts compared to the revisional port procedures.

Table 1

| Variable                                      | Primary Procedures (n = 112) | Revisional procedures (n = 100) | \( P \)-value |
|-----------------------------------------------|------------------------------|---------------------------------|--------------|
| Gender                                        |                              |                                 | .003         |
| Female, n (%)                                 | 86 (76.8)                    | 76 (76.0)                       |              |
| Age (yr), median (range)                      | 47.0 (18.0–69.0)             | 48.5 (23.0–71.0)                |              |
| Weight (kg), median (range)                   | 135.5 (89.0–210.5)           | 112.0 (89.0–210.5)              | \(< .001\)   |
| BM (kg/m\(^2\)), median (range)               | 48.9 (36.2–75.3)             | 38.6 (34.6–62.5)                | \(< .001\)   |
| TED/SCD                                       | Yes, n (%)                   | Yes, n (%)                      | \(< .001\)   |
| Length of hospital stay, n (%)                 |                              |                                 |              |
| Day procedure only                            | 0 (0.0)                      | 7 (7.0)                         |              |
| 1 day                                         | 103 (92.0)                   | 10 (10.0)                       |              |
| 2 days                                        | 6 (5.4)                      | 5 (5.0)                         |              |
| 3 days                                        | 3 (2.7)                      | 0 (0.0)                         | .004         |
| 4 days                                        | 0 (0.0)                      | 2 (2.0)                         |              |
| Days, median (range)                          | 1 (1–3)                      | 1 (1–4)                         |              |
| Duration of surgery (min), median (range)     | 48.5 (30.0–113.0)            | 64.0 (25.0–145.0)               | \(< .001\)   |
| ASA score                                     |                              |                                 |              |
| 1, n (%)                                      | 0 (0.0)                      | 1 (1.0)                         |              |
| 2, n (%)                                      | 36 (32.1)                    | 9 (9.0)                         |              |
| 3, n (%)                                      | 76 (67.9)                    | 13 (13.0)                       |              |
| 4, n (%)                                      | 0 (0.0)                      | 1 (1.0)                         |              |
| Congestive heart failure                      | Yes, n (%)                   |                                 |              |
| Paraplegia                                    | 2 (1.8)                      | 1 (1.0)                         |              |
| Return to operating room                     | Yes, n (%)                   | 0 (0.0)                         |              |
| Dyspnea at rest                               | Yes, n (%)                   | 0 (0.0)                         |              |
| Smoker                                        | 6 (5.4)                      | 1 (1.0)                         |              |
| Diabetes mellitus                             | Yes, n (%)                   | 26 (23.2)                       | \( P < .05 \) |
| Hypertension                                  | Yes, n (%)                   | 43 (38.4)                       | \( P < .05 \) |
| VTE history                                   | Yes, n (%)                   | 50 (44.5)                       |              |
| Obstructive sleep apnoea                      | Yes, n (%)                   | 3 (2.7)                         |              |
| Oral contraceptive/hormone replacement therapy| Yes, n (%)                   | 32 (28.6)                       | \( P < .05 \) |
| VTE risk                                      | Yes, n (%)                   | 7 (6.2)                         | \( P < .05 \) |

Only statistically significant values (\( P < .05 \)) are shown under the \( P \)-value column.
procedure cohort (100% and 79%, vs 20%; *P* < .001). The majority of patients in the primary and revisional (band and port) cohorts received 40mg enoxaparin once daily (Table 2). All patients in the primary procedure cohort received prophylactic enoxaparin post-discharge, typically for 10 days, compared to 54% of revisional band procedure and just 5% of revisional port procedure patients. The multivariate logistic regression model showed that patients who stayed longer in hospital (typically those who had undergone primary LAGB and band procedures) were more likely to receive chemoprophylaxis (Table 3); that is, enoxaparin use was higher in patients who had an overnight stay in hospital.

### Table 2
Thromboprophylaxis practices and outcomes (N = 212).

| Regimen                              | Primary procedures (n = 112) | Revisional procedures (n = 100) | P-value |
|--------------------------------------|----------------------------|--------------------------------|---------|
| TED/SCD only, n (%)                  | 0 (0.0)                    | 5 (20.8)                      | .001    |
| Enoxaparin only, n (%)               | 0 (0.0)                    | 1 (4.2)                       |         |
| TED/SCD and Enoxaparin, n (%)        | 112 (100.0)                | 18 (75.0)                     |         |
| None, n (%)                          | 0 (0.0)                    | 0 (0.0)                       |         |
| Peri-operative anticoagulant         |                            |                                |         |
| Enoxaparin 40 mg daily, n (%)        | 111 (99.1)                 | 17 (70.8)                     | .001    |
| Enoxaparin 60 mg daily, n (%)        | 0 (0.0)                    | 0 (0.0)                       |         |
| Enoxaparin 80 mg daily, n (%)        | 1 (0.9)                    | 0 (0.0)                       |         |
| None, n (%)                          | 0 (0.0)                    | 7 (29.2)                      |         |
| Post-operative anticoagulant         |                            |                                |         |
| Enoxaparin 40 mg daily, n (%)        | 110 (98.2)                 | 16 (66.7)                     | .001    |
| Enoxaparin 60 mg daily, n (%)        | 1 (0.9)                    | 0 (0.0)                       |         |
| Enoxaparin 80 mg daily, n (%)        | 1 (0.9)                    | 0 (0.0)                       |         |
| None, n (%)                          | 0 (0.0)                    | 8 (33.3)                      | .001    |
| Duration of chemoprophylaxis         |                            |                                |         |
| Peri-op only, n (%)                  | 0 (0.0)                    | 3 (12.5)                      | .001    |
| Peri-op until discharge, n (%)       | 0 (0.0)                    | 1 (4.2)                       |         |
| Post-op until discharge, n (%)       | 0 (0.0)                    | 2 (8.3)                       |         |
| 10 d post-discharge, n (%)           | 110 (98.2)                 | 13 (54.2)                     |         |
| 30 d post-discharge, n (%)           | 2 (1.8)                    | 0 (0.0)                       |         |
| None, n (%)                          | 0 (0.0)                    | 5 (20.8)                      |         |
| Enoxaparin use*                      |                            |                                | .001    |
| Yes, n (%)                           | 112 (100)                  | 19 (79.2)                     |         |
| VTE within 90-d, n (%)               | 1 (0.9)                    | 0 (0.0)                       |         |
| Major bleed within 90 d, n (%)       | 0 (0.0)                    | 0 (0.0)                       |         |

Statistically significant values (*P* < .05) are shown in italics under the *P*-value column to highlight such significance.

*Any of the following regimen of enoxaparin: start at induction until discharge, start post-operatively until discharge, start at induction until post-discharge, or start post-operatively until post-discharge.

### Table 3
Logistic regression for variables associated with enoxaparin use (n = 212).

| Variable               | Unadjusted OR (95% CI) | *P*-value | Adjusted OR (95% CI) | *P*-value |
|------------------------|------------------------|-----------|----------------------|-----------|
| Gender                 |                        |           |                      |           |
| Female                 | 0.49 (0.21–1.13)       | .09       | 2.09 (0.32–13.64)    | .44       |
| Age                    | 0.99 (0.96–1.02)       | .86       |                      |           |
| Procedure              |                        |           |                      |           |
| Primary                | 0.00 (0.00–0.00)       | .99       | 0.00 (0.00–0.00)     | .99       |
| Duration of surgery (mi) | 1.03 (1.01–1.06)       | .001      | 1.02 (0.99–1.06)     | .15       |
| BMI                    | 1.08 (1.04–1.12)       | <.001     | 1.03 (0.94–1.12)     | .45       |
| Overnight stay*        |                        |           |                      |           |
| Day procedure          | 307.78 (86.92–1080.87) | <.001     | 33.32 (7.99–130.00)  | <.001     |
| ASA score              |                        |           |                      |           |
| 1                      | 1.91 (0.11–32.00)      | .65       |                      |           |
| Smoker                 | 1.15 (0.58–2.92)       | .68       |                      |           |
| VTE risk               |                        |           |                      |           |
| Mild                   | 1.84 (0.20–16.82)      | .59       | 0.00 (0.00–0.00)     | .99       |

ASA = American Society of Anesthesiologist, BMI = body mass index, CI = confidence interval, OR = odds ratio.

Variables with *P*-value less than .15 and other factors which were associated with anticoagulant use (procedure type and VTE risk) were considered in multivariate regression analysis.

VTE risk is categorised into mild and moderate/severe.

*Overnight stay is categorized into ≥ 1 d or day procedure (0 d).
There was 1 VTE occurrence in each of the primary and revisional port procedure cohorts. Both patients were taking HRT. One patient (210 kg; BMI 75.3 kg/m²) who underwent primary LAGB was diagnosed with a deep vein thrombosis 35 days post-operatively. This patient had received 40 mg enoxaparin at induction and 40 mg enoxaparin daily for 10 days post-discharge. The other patient (118 kg; BMI 49.1 kg/m²) had undergone a port adjustment and was diagnosed with pulmonary embolism 2 months post-operatively, after reporting 4 weeks of shortness of breath. This patient had received only mechanical prophylaxis during hospital stay and no chemoprophylaxis. Two other primary procedure patients developed possible clinical manifestations of VTE (pain and calf swelling). These patients underwent diagnostic procedures (colour Doppler ultrasound and CT pulmonary angiography) but no VTE was detected in either patient. There was no significant difference in the overall occurrence of VTE between the primary and revisional procedure cohorts (0.9% vs 1.0% respectively; P-value = 1.00). No major bleeding event was observed in either cohort. Similarly, there was no statistically significant difference in the overall 90-day VTE incidence between the cohorts who received and did not receive chemoprophylaxis (0.7% vs 1.5%, respectively; P-value = .58).

The majority of clinical and demographic variables in our primary procedure cohort were similar to those reported in the American College of Surgeons-National Surgical Quality Improvement Programme (ACS-NSQIP) and SNIIRM databases. The reported incidences of VTE in primary LAGB patients in the ACS-NSQIP (30 days) and the SNIIRM databases (90 days) were 0.1% (26/24,650) and 0.2% (31/14,947), respectively.14,17 Our study’s 30-day and 90-day VTE incidences were not significantly different compared to the ACS-NSQIP database (0.0% vs 1.1%, P-value = .63, 95% CI = 0.00–3.24) and the SNIIRM database (0.9% vs 0.2%, P-value = .09, 95% CI = 0.02–4.89), respectively.

4. Discussion
We observed low incidences of VTE and no major bleeds in both primary and revisional LAGB procedures. Surgical procedures performed laparoscopically are less likely to result in postoperative VTE compared to open procedures.18 However, guidelines such as those of ASMBS, CHEST and NICE do not recommend specific VTE prophylaxis for LAGB. These guidelines suggest the same prophylactic chemoprophylactic approach based on the individual patient risk assessment (VTE vs bleeding risk) and clinical judgment of the surgeon for all bariatric procedures regardless of type (gastric banding, gastric bypass, and sleeve gastrectomy) or technique (laparoscopic or open).4,6 Despite the mild risk of VTE development, all of our primary LAGB procedure patients received chemoprophylaxis.

LAGB is considered the safest bariatric procedure in terms of VTE risk.19 According to the ACS-NSQIP database, the 30-day prevalence of VTE following LAGB was 0.1% compared to 0.6% and 0.4% in laparoscopic sleeve gastrectomy and laparoscopic gastric reduction patients, respectively.14 Similarly, according to the SNIIRM database, the reported incidence of 90-day VTE with LAGB was lower (0.2%) compared to laparoscopic sleeve gastrectomy (0.5%) and laparoscopic gastric reduction (0.6%).17 A German nationwide survey reported a gradually declining trend of chemoprophylaxis in LAGB surgery from 2005 (100%) till 2010 (95%), due to shorter length of hospital stay and less complicated procedures.20

A total of 97% of patients who had mild risk of VTE development received chemoprophylaxis. Yet, studies of laparoscopic bariatric surgery have reported that mechanical prophylaxis alone provides sufficient VTE prophylaxis if the operation time is short and the patient becomes ambulatory soon after surgery.8,21 Our patients fulfilled both of these criteria; the mean operation time was shorter (mean = 49.7 minutes) compared to sleeve gastrectomy (100 minutes) and gastric bypass (135 minutes) patients reported in the ACS-NSQIP database,14 and the majority of our patients were ambulatory on the day of surgery, likely due to the less complex surgical procedure.

A 10-year longitudinal study reported that LAGB resulted in a higher surgical revision rate compared to gastric bypass and sleeve gastrectomy.21 This is a possible explanation for the relatively high number of revisional procedures in our study, because LAGB has been the principal bariatric procedure conducted at our study site since the late 1990s. The mean duration from primary to revisional procedures was 7.36 years in our study patients.

This study had some limitations. First, the retrospective study design meant that we had to rely on the notes available in digital medical records, and verbal advice from the principal bariatric surgeon. Secondly, our sample size was relatively small, with limited statistical power when examining relatively rare outcomes. Thirdly, we did not screen all patients for VTE after their surgery, so the incidence may have been under-reported. Lastly, LAGB is now not a first-choice bariatric procedure in many countries, including USA, but this is still widely employed in other countries.

5. Conclusion
A low incidence of VTE was observed in the LAGB surgical cases in this study, which included a heterogenous mix of primary and revisional surgeries, with varying use, dose, and duration of enoxaparin. Because of the low VTE risk associated with LAGB, chemoprophylaxis may not be required in all patients unless there are additional risk factors, such as super-super-morbid obesity (BMI >60 kg/m²) or concomitant HRT. As there is no procedure- and technique-specific thromboprophylaxis advice for bariatric surgery, surgeons should follow current recommendations, modifying them as required to suit individual patients’ risk. Further research to provide procedure- and technique-specific thromboprophylaxis evidence may improve outcomes.

Acknowledgments
We are grateful to Dr Karl Gadd (Specialist Anaesthetist, Launceston General Hospital, Tasmania, Australia) for his valuable inputs in the preparation of this manuscript.

Author contributions
Zahid Hussain: Study concept and design, data collection and analysis, manuscript drafting and revisions.
Gregory M Peterson: Study design, interpretation of data, manuscript revision.
Corinne Mirkazemi: Study design, manuscript revision.
Colin Curtain: Interpretation of data, manuscript revision.
Syed Tabish R. Zaidi: Study concept, manuscript revision
References

[1] Lee WJ, Almalki O. Recent advancements in bariatric/metabolic surgery. Ann Gastroenterol Surg 2017;1:171–9.
[2] Weight loss surgery in Australia 2014-15: Australian hospital statistics. Australian Institute of Health and Welfare Australia 2015. Available from: https://www.aihw.gov.au/reports/overweight-obesity/abs-2014-15-weight-loss-surgery/contents/table-of-contents. Accessed December 17, 2018.
[3] Dang JT, Switzer N, Delisle M, et al. Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database. Surg Endosc 2018;33:821–31.
[4] Brethauer SA. ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis 2013;9:493–7.
[5] Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e227S–S37.
[6] Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. National Institute for Health and Care Excellence UK 2018. Available from: https://www.nice.org.uk/guidance/ng89/evidence/full-guideline-volume-1-pdf-4787002765. Accessed January 6, 2019.
[7] Birkmeyer NJ, Finks JF, Carlin AM, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. Arch Surg 2012;147:994–8.
[8] Gonzalez Q, Tishler D, Plata-Munoz J, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2004;18:1042–4.
[9] Clements RH, Yellumahanthi K, Ballem N, et al. Pharmacologic prophylaxis against venous thromboembolic complications is not mandatory for all laparoscopic Roux-en-Y gastric bypass procedures. J Am Coll Surg 2009;208:917–21.
[10] Ojo P, Asyamboju B, Valin E, et al. Post discharge prophylactic anticoagulation in gastric bypass patient—how safe? Obes Surg 2008;18:791–6.
[11] Borkgren-Okonke MJ, Hart RW, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antithrombin Vivi activity, Surg Obes Relat Dis 2008;4:625–31.
[12] Raptopoulos I, Martindale C, Cronn A, et al. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc 2008;22:2384–91.
[13] Woo HD, Kim YJ. Prevention of venous thromboembolism with enoxaparin in bariatric surgery. J Korean Surg Soc 2013;84:298–303.
[14] Aminian A, Andalib A, Khorgami Z, et al. Who should get extended thromboprophylaxis after bariatric surgery? Ann Surg 2017;265:143–50.
[15] ASA Physical Status Classification System USA. 2014. Available from: https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system. Accessed January 7, 2019.
[16] Schulman S, Angeràs U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202–4.
[17] Thereaux J, Lesuffleur T, Czernichow S. To what extent does posthospital discharge chemoprophylaxis prevent venous thromboembolism after bariatric surgery? Results from a nationwide cohort of more than 110,000 patients. Ann Surg 2018;267:727–33.
[18] Nguyen NT, Hnojosa MW, Fayad , et al. Laparoscopic surgery is associated with a lower incidence of venous thromboembolism compared with open surgery. Ann Surg 2007;246:1021–7.
[19] Finks JF, English WJ, Carlin AM, et al. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 2012;255:1100–4.
[20] Stroh C, Luderer D, Weiner R, et al. Actual situation of thromboembolic prophylaxis in obesity surgery: data of quality assurance in bariatric surgery in Germany. Thrombosis 2012. Article ID 209052; doi: 10.1133/2012/209052.
[21] Suter M, Calmes J, Paroz A, et al. A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. Obes Surg 2006;16:829–35.